Lack of effect of diacetyl-splenopentin (Berlopentin) on the pharmacokinetics of caffeine.
The influence of Berlopentin on caffeine clearance was measured after a 6 week i.v. treatment or a 4 week s.c. administration within a phase I trial. It was demonstrated that therapy with Berlopentin did not affect significantly caffeine elimination. Thus, clearance of drugs which are biotransformed by hepatic microsomal oxidation are unlikely to be affected by the coadministration of Berlopentin.
Simon
H U
HU
Institut für Klinische Immunologie, Friedrich-Schiller-Universität Jena.
Kraul
H
H
Schäfer
R
R
Kilian
U
U
Hoffmann
A
A
D000328:Adult; D000595:Amino Acid Sequence; D002110:Caffeine / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008969:Molecular Sequence Data; D010084:Oxidation-Reduction; D010446:Peptide Fragments / Q000494:pharmacology*; D013946:Thymopoietins / Q000494:pharmacology*
D010446:Peptide Fragments; D013946:Thymopoietins; D002110:Caffeine; C060485:berlopentin